Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts HOWL Hot Sheet
Join SI Premium – FREE
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.14), $0.28 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $8.08 million versus the consensus estimate of $7.85 million.
For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- BTIG sees S&P 500 ETF stock volume hit 22-year low on quiet calendar
- Marvell Technology shares fall on valuation concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
